265 related articles for article (PubMed ID: 38139377)
1. Metabolomic Signatures of Treatment Response in Bladder Cancer.
Vieira de Sousa T; Guedes de Pinho P; Pinto J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139377
[TBL] [Abstract][Full Text] [Related]
2. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
Zheng Y; Ye Y; Chen J; Wei Z; Liu Z; Yu K; Zhang X
Int J Surg; 2022 Jul; 103():106693. PubMed ID: 35690361
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review).
Shahid M; Yeon A; Kim J
Mol Med Rep; 2020 Dec; 22(6):5003-5011. PubMed ID: 33174036
[TBL] [Abstract][Full Text] [Related]
5. Bladder sparing surgery in high-grade bladder cancer.
Yakovlev PG; Klyushin DA; Vereshchako RI
Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
Rodrigues D; Jerónimo C; Henrique R; Belo L; de Lourdes Bastos M; de Pinho PG; Carvalho M
Int J Cancer; 2016 Jul; 139(2):256-68. PubMed ID: 26804544
[TBL] [Abstract][Full Text] [Related]
7. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
[TBL] [Abstract][Full Text] [Related]
8. Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor (TURBT)-Dependent Practice.
Taguchi S; Watanabe M; Tambo M; Machida H; Yokoyama K; Fukuhara H
Clin Genitourin Cancer; 2022 Aug; 20(4):e291-e295. PubMed ID: 35346591
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
10. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
[TBL] [Abstract][Full Text] [Related]
11. Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry.
Rodrigues D; Pinto J; Araújo AM; Monteiro-Reis S; Jerónimo C; Henrique R; de Lourdes Bastos M; de Pinho PG; Carvalho M
Metabolomics; 2018 Apr; 14(5):62. PubMed ID: 30830384
[TBL] [Abstract][Full Text] [Related]
12. Discovery of urine biomarkers for bladder cancer via global metabolomics.
Shi H; Li X; Zhang Q; Yang H; Zhang X
Biomarkers; 2016 Nov; 21(7):578-88. PubMed ID: 27133288
[TBL] [Abstract][Full Text] [Related]
13. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.
Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM
Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.
di Meo NA; Loizzo D; Pandolfo SD; Autorino R; Ferro M; Porta C; Stella A; Bizzoca C; Vincenti L; Crocetto F; Tataru OS; Rutigliano M; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456991
[TBL] [Abstract][Full Text] [Related]
16. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?
Kaimakliotis HZ; Monn MF; Cary KC; Pedrosa JA; Rice K; Masterson TA; Gardner TA; Hahn NM; Foster RS; Bihrle R; Cheng L; Koch MO
Urol Oncol; 2014 Aug; 32(6):833-8. PubMed ID: 24954925
[TBL] [Abstract][Full Text] [Related]
17. The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy.
Abd El-Latif A; Watts KE; Elson P; Fergany A; Hansel DE
J Urol; 2013 Apr; 189(4):1263-7. PubMed ID: 23085297
[TBL] [Abstract][Full Text] [Related]
18. Radical Transurethral Resection of Bladder Tumor in Seemingly Organ-confined Muscle-invasive Bladder Cancer: Con.
Maas M; Black PC
Eur Urol Focus; 2023 Mar; 9(2):223-224. PubMed ID: 36220762
[TBL] [Abstract][Full Text] [Related]
19. Optimal timing of radical cystectomy for patients with T1 bladder cancer.
Bochner BH
Urol Oncol; 2009; 27(3):329-31. PubMed ID: 19414124
[TBL] [Abstract][Full Text] [Related]
20. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
